Hydroxychloroquine (All indications except Antiphospholipid Syndrom)

Nervous system anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13651
R52969		 Cooper (controls exposed to TNF-I), 2014 Central nervous system defects 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 0.86 [0.03;21.53] C
excluded (control group) 		1/194   0/56 1 194
ref
S13652
R52999		 Cooper (controls unexposed, sick), 2014 Central nervous system defects 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 2.66 [0.11;65.66] C 1/194   0/171 1 194
ref
Total 1 studies 2.66 [0.11;65.66] 1 194
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Cooper (controls unexposed, sick), 2014Cooper, 2014 1 2.66[0.11; 65.66]11940%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate0.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.66[0.11; 65.66]1194 -NACooper (controls unexposed, sick), 2014 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 2.66[0.11; 65.66]1194 -NACooper (controls unexposed, sick), 2014 1 Tags Adjustment   - No  - No 2.66[0.11; 65.66]1194 -NACooper (controls unexposed, sick), 2014 1 Indication HCQ   - Rheumatic diseases as a whole (Syst ...  - Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 2.66[0.11; 65.66]1194 -NACooper (controls unexposed, sick), 2014 1 All studiesAll studies 2.66[0.11; 65.66]1194 -NACooper (controls unexposed, sick), 2014 10.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 13651

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 2.66[0.11; 65.66]1194 -NACooper (controls unexposed, sick), 2014 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.86[0.03; 21.53]1194 -NACooper (controls exposed to TNF-I), 2014 10.510.01.0

Umbrella review (other published meta-analyses)

Published MATE95% CIn exposedkI2Control groupExposition period Kaplan (All indications)Kaplan (All indications) 1.81[0.31; 10.52]0%-whatever (meta-analysis)at least 1st trimesterstudies3 metaPregmetaPreg 2.66[0.11; 65.66]NaN%194--Cooper (controls unexposed, sick), 2014 10.510.01.0